Deng, Chenhui

12Linking Truth Technology Co, Ltd, Beijing, China.

1 paper on CoChat

Most cited papers

Verified
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
Papadopoulos, K. P., Borazanci, E., Shaw, A. T., Katayama, R., Shimizu, Y., Zhu, V. W., Sun, T. Y., Wakelee, H. A., Madison, R., Schrock, A. B., et al. (2020) · Clinical Cancer Research
Lung Cancer Treatments and MutationsCancer Mechanisms and Therapy
Cited by 113

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free